Stock Exchange:
Copenhague
Sector:
Biotechnology
Sub-sector:
Development
Turnover last year:
16.747 MDKK 2023
Profits last year:
4.352 MDKK 2023
Activity: Antibodies for cancer.
GENMAB is an biotechnology company specialising in the creation and development of human antibody therapies for the treatment of cancer.
OPEN GRAPHIC
